HC Wainwright Issues Positive Forecast for Omeros Earnings

Omeros Corporation (NASDAQ:OMER) – Analysts at HC Wainwright lifted their Q2 2026 earnings estimates for shares of Omeros in a report released on Thursday, May 14th. HC Wainwright analyst B. Folkes now forecasts that the biopharmaceutical company will post earnings per share of ($0.27) for the quarter, up from their prior forecast of ($0.39). HC Wainwright currently has a “Buy” rating and a $40.00 price objective on the stock. The consensus estimate for Omeros’ current full-year earnings is ($0.32) per share. HC Wainwright also issued estimates for Omeros’ Q3 2026 earnings at ($0.22) EPS, Q4 2026 earnings at ($0.21) EPS, FY2026 earnings at ($0.94) EPS, FY2028 earnings at $2.43 EPS, FY2029 earnings at $4.30 EPS and FY2030 earnings at $5.47 EPS.

Omeros (NASDAQ:OMER) last announced its quarterly earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.16. The company had revenue of $9.89 million during the quarter, compared to analyst estimates of $4.19 million.

Several other equities analysts have also weighed in on the stock. Weiss Ratings upgraded shares of Omeros from a “sell (d-)” rating to a “hold (c-)” rating in a report on Thursday. D. Boral Capital restated a “buy” rating and set a $36.00 target price on shares of Omeros in a report on Tuesday, April 21st. Zacks Research upgraded shares of Omeros from a “hold” rating to a “strong-buy” rating in a report on Thursday, April 2nd. Finally, Wall Street Zen lowered shares of Omeros from a “buy” rating to a “hold” rating in a report on Sunday, April 26th. Two analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $40.33.

Omeros Stock Down 4.5%

Shares of OMER opened at $11.70 on Tuesday. The firm has a market cap of $846.85 million, a PE ratio of 16.71 and a beta of 2.66. The company’s fifty day moving average is $12.27 and its two-hundred day moving average is $11.45. Omeros has a fifty-two week low of $2.95 and a fifty-two week high of $17.65.

Institutional Investors Weigh In On Omeros

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. State of Wyoming purchased a new stake in Omeros during the 4th quarter worth $25,000. B. Riley Wealth Advisors Inc. purchased a new stake in Omeros during the 2nd quarter worth $32,000. Caitong International Asset Management Co. Ltd purchased a new stake in Omeros during the 4th quarter worth $33,000. Assetmark Inc. purchased a new stake in Omeros during the 1st quarter worth $38,000. Finally, Tower Research Capital LLC TRC increased its stake in Omeros by 829.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 13,414 shares of the biopharmaceutical company’s stock worth $40,000 after buying an additional 11,971 shares during the period. Hedge funds and other institutional investors own 48.79% of the company’s stock.

About Omeros

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.